Learn more about our pioneering research in taking on one of cancer research’s toughest challenges, and hear first-hand from patients and Amgen scientists.
Follow Amgen Oncology on Twitter and LinkedIn for the latest updates and learn more about Amgen's commitment to the relentless pursuit of breakthroughs for cancer patients with NSCLC and other solid tumors with KRAS G12C mutations at AmgenOncology.com.